Streetbeat News

UCBJY

UCB SA

https://www.ucb.com

CEO

Jean-Christophe Tellier

Industry

Pharmaceutical Preparation Manufacturing

Open

99.14

Mkt cap

38B

Volume

1.3K

High

99.17

P/E Ratio

150.26

52-wk high

99.17

Low

99.00

Div yield

0.00

52-wk low

34.85

Biogen and UCB's Phase 3 study of dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, showing improvement over placebo. A second Phase 3 trial is planned for 2024. Biogen's stock rose 1.66% in premarket trading.

Portfolio Pulse from Vandana Singh

September 24, 2024 | 12:19 pm

Truist Securities initiated coverage on Longboard Pharmaceuticals (NASDAQ:LBPH), highlighting its high-value epilepsy assets. The company plans to advance its lead drug, bexicaserin, into Phase 3 trials. Bexicaserin has shown promising results in reducing seizures and has received FDA Breakthrough Therapy designation. Truist rates LBPH as a Buy with a $60 price target, citing bexicaserin's superior safety and potential to expand the epilepsy market.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 6:13 pm

Johnson & Johnson has submitted a Biologics License Application to the FDA for nipocalimab, a drug for generalized myasthenia gravis (gMG). This marks the first FDA submission for nipocalimab, which showed positive results in a Phase 3 study. The drug will compete with UCB's Rystiggo and Argenx's Vyvgart in the gMG market.

Portfolio Pulse from Vandana Singh

August 29, 2024 | 4:29 pm

UCB SA, a European biopharmaceutical company, is divesting its neurology and allergy business in China for $680 million to CBC Group and Mubadala. This strategic move allows UCB to focus on innovation and partnerships in China, with the transaction expected to close in Q4 2024.

Portfolio Pulse from Vandana Singh

August 26, 2024 | 11:51 am

Longboard Pharmaceuticals Inc (NASDAQ:LBPH) released positive topline data from the PACIFIC Phase 1b/2a study for its anti-seizure candidate bexicaserin, showing a median 53% reduction in seizures. Cantor Fitzgerald raised LBPH's price target from $35 to $55 and maintained an overweight rating, citing the drug's potential to achieve over $1 billion in peak sales. LBPH shares surged 222.60% to $19.45 following the news.

Portfolio Pulse from Vandana Singh

January 02, 2024 | 6:55 pm

Raymond James initiated coverage on Dianthus Therapeutics Inc (DNTH) with an Outperform rating and a price target of $24. The company's lead asset, DNTH103, is an antibody designed to target active C1s and is protected by intellectual property rights until 2043. Dianthus is initiating a Phase 2 gMG study with a target product profile that will potentially offer dosing advantages and safety advantages over prevailing comps. Phase 2 data are expected by 2H25.

Portfolio Pulse from Vandana Singh

September 28, 2023 | 7:33 pm

Needham has initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating and a price target of $76. The company's lead product, sonelokimab (SLK), is seen as a potential best-in-class treatment for chronic dermatological ailments, outperforming established biologics. The market opportunity for SLK is estimated at $30 billion, expected to grow to $40-$50 billion by the mid-2030s. Needham sees UCB SA's (OTC:UCBJY) (OTC:UCBJF) bimekizumab and izokibep by Acelyrin Inc (NASDAQ: SLRN) as the main competitors to SLK.

Portfolio Pulse from Vandana Singh

August 31, 2023 | 5:38 pm

The FDA has approved UCB SA's Rystiggo for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive. Rystiggo is the only FDA-approved treatment for these two most common subtypes of gMG. The approval is based on data from the Phase 3 MycarinG study. Rystiggo will be commercially available in the U.S. in Q3 2023. Last week, the FDA also approved Argenx SE's Vyvgart Hytrulo for gMG in adult patients who are anti-acetylcholine receptor antibody positive.

Portfolio Pulse from Vandana Singh

June 27, 2023 | 5:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.